Movement Alert｜HANSOH PHARMA Rises 3.65% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Drive Momentum

Market Focus08-10 13:13

On August 10, HANSOH PHARMA rose 3.65% in regular trading, trading at HK$33.9/share, with turnover of HK$320 million. The stock's upward move was driven by a series of recent pipeline catalysts and a favorable analyst outlook.

On August 6, the company announced that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration (NMPA) for treating adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. CLSA maintained its Outperform rating and raised the target price to HK$42, forecasting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, projecting revenue growth of 14%, 10%, and 14% respectively over the next three years.

Additionally, the company's core ADC candidate HS-20093 recently met primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications being prepared. The company's interim results are scheduled for disclosure on August 26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149044806?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 13:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149044806","market":"us","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 3.65% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Drive Momentum","media":"Market Focus","content":"<p><p>On August 10, HANSOH PHARMA rose 3.65% in regular trading, trading at HK$33.9/share, with turnover of HK$320 million. The stock's upward move was driven by a series of recent pipeline catalysts and a favorable analyst outlook.</p><p>On August 6, the company announced that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration (NMPA) for treating adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. CLSA maintained its Outperform rating and raised the target price to HK$42, forecasting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, projecting revenue growth of 14%, 10%, and 14% respectively over the next three years.</p><p>Additionally, the company's core ADC candidate HS-20093 recently met primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications being prepared. The company's interim results are scheduled for disclosure on August 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 3.65% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 3.65% in Regular Trading, New Drug Clinical Approval and Pipeline Milestones Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 13:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, HANSOH PHARMA rose 3.65% in regular trading, trading at HK$33.9/share, with turnover of HK$320 million. The stock's upward move was driven by a series of recent pipeline catalysts and a favorable analyst outlook.</p><p>On August 6, the company announced that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration (NMPA) for treating adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. CLSA maintained its Outperform rating and raised the target price to HK$42, forecasting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, projecting revenue growth of 14%, 10%, and 14% respectively over the next three years.</p><p>Additionally, the company's core ADC candidate HS-20093 recently met primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications being prepared. The company's interim results are scheduled for disclosure on August 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1149044806","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149044806","pubTimestamp":1786338802,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, HANSOH PHARMA rose 3.65% in regular trading, trading at HK$33.9/share, with turnover of HK$320 million. The stock's upward move was driven by a series of recent pipeline catalysts and a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"动向提醒|豪森制药常规交易涨3.65%，新药临床获批及管线里程碑推动动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On August 10, HANSOH PHARMA rose 3.65% in regular trading, trading at HK$33.9/share, with turnover of HK$320 million. The stock's upward move was driven by a series of recent pipeline catalysts and a favorable analyst outlook.On August 6, the company announced that its proprietary Class 1 new drug HS-10582 tablets received clinical trial approval from China's National Medical Products Administration (NMPA) for treating adult primary hypercholesterolemia and mixed dyslipidemia, adding a new candidate to its cardiovascular-metabolic pipeline. CLSA maintained its Outperform rating and raised the target price to HK$42, forecasting five new drug approvals next year including B7-H3 ADC, Olatorepatide, c-MET, and RET inhibitors, projecting revenue growth of 14%, 10%, and 14% respectively over the next three years.Additionally, the company's core ADC candidate HS-20093 recently met primary endpoints in Phase 3 trials for both osteosarcoma and small cell lung cancer, with biologics license applications being prepared. The company's interim results are scheduled for disclosure on August 26.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149044806","isCrawlerRequest":true}